Notice of Proposed Sale · 144
Xenon Pharmaceuticals Inc.
XENENASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- XENON PHARMACEUTICALS INC
- Issuer CIK
- 0001582313
- SEC file number
- 001-36687
- Phone
- 6044843300
- Person for whose account securities are to be sold
- CHRISTOPHER KENNEY
- Relationships to issuer
- Officer
- Street
- 3650 Gilmore Way
- City
- Burnaby
- State / country code
- A1
- Postal code
- V5G4W8
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 7,068 | 437,721.24 | 96,840,432 | 08/28/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 03/09/2026 | Restricted and Performance Stock Units | Issuer | 7,068 | N | 03/09/2026 | N/A |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
The securities to be sold were acquired upon the vesting of restricted and performance stock units on 03/09/2026 and 03/12/2026.
Notice signature
- Notice date
- 08/28/2026
- Signed
- /s/ Christopher Kenney
- Plan adoption dates
- 05/29/2026
Company context
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent KV7 potassium channel opener in late-stage clinical development for the treatment of epilepsy, major depressive disorder and bipolar depression. Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.